Sandoz aims to double sales in Japan by 2022

Sandoz, a Novartis division, plans to double sales in Japan by 2022 period as part of a long-term strategy to deliver better access to high quality medicines to the Asian nation.
“Our Purpose at Sandoz is to increase patient access by helping more people around the world obtain high quality medicines at affordable prices,” Sandoz CEO and Division Head Richard Francis said in a statement. “To deliver on this goal of making access happen, we need to focus our efforts on the markets where we can really make a difference for the patients we serve.”
To that end, the company is focusing on Japan. The government in Japan hopes to raise generic medicine share to 80 percent by 2020. Against the backdrop of that, Sandoz will aim to accelerate the launch of medicine products in the country, focusing primarily on oncology, central nervous system medications, and biosimilars.
“Japan is a priority market for Sandoz,” Francise said. “It combines a real and growing need to increase patient access to affordable high-quality medicines with a government that is committed to actively driving the market share of high-quality generic medicines.”